ASCO Provides Input on CMMI's
ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.
Balancing Drug Breakthroughs with Rising Drug Costs
Hepatitis C and the price of Sovaldi were, understandably, the main focus of aconversation on rising prescription drug prices at the America’s Health Insurance Plans’ National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC.
Avoid Unnecessary Pap Tests: Study Concludes
A study published in the American Journal of Preventive Medicine found that lack of awareness resulted in women over 65 and those who had undergone hysterectomy routinely undergoing a Pap test.
A Look at the Future of Medicaid and Rate Setting
At $531 billion, Medicaid is the second largest piece of healthcare spending and cannot be pushed off to be thought about another day, Cindy Mann, JD, CMS deputy administrator and director of the Center for Medicaid and CHIP Services, said at the America’s Health Insurance Plans’ National Conferences on Medicare and Medicaid and Dual Eligibles Summit.
ESMO 2014: New Regimen for BRAF-mutated Melanoma
Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.
Reforming the Healthcare Delivery System
At the America’s Health Insurance Plans’ National Conference on Medicare and Medicaid and Dual Eligibles Summit in Washington, DC, Patrick Conway, deputy administrator for innovation and quality and chief medical officer for CMS, spoke on the future of delivery system reform.
JCO Study: MMA Did Not Influence Fee-For-Service Prescribing
The study by Kaiser Permanente found that prescription practices were not much influenced by the decrease in fee-for-service payments for outpatient chemotherapy, due the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
ESMO 2014: Nivolumab Promise in Melanoma
Results from the CheckMate-037 trial showed a significant increase in duration of response in patients with advanced melanoma administered nivolumab as second- or third-line therapy
Costs Can Go Up Fast When ER Is in Network but the Doctors Are Not
Even the most basic visits with emergency room physicians and other doctors called in to consult are increasingly leaving patients with hefty bills: More and more, doctors who work in emergency rooms are private contractors who are out of network or do not accept any insurance plans.
Employers May Find Savings From ACOs, Journal Reports
The accountable care organization, or ACO, can be a mechanism for employers to achieve healthcare savings, according to a just-published article in The American Journal of Accountable Care, the publication of The American Journal of Managed Care
dedicated to healthcare reform.
Without Teens in Cancer Trials, Cure Rates Won’t Improve
Fictional teens with cancer may be suddenly popular in film and TV, but they are hard to find in the one place where they are most needed: in clinical trials to find drugs to save their lives. A story in the new issue of Evidence-Based Oncology
, a publication of The American Journal of Managed Care
, examines this problem.
AJMC Review Offers Roadmap for Getting Paid in Molecular Diagnostics
Both Medicare and commercial insurers have raised the bar for molecular diagnostic companies, requiring them to show clinical utility to receive reimbursement for cellular tests designed to guide treatment in cancer, rheumatoid arthritis, and other diseases. An important new article in The American Journal of Managed Care
reviews cases from a top Medicare contractor and outlines how to build the evidence to meet today’s standards.